Online Office System

Journal Online

    column
    Research progress in nano-drug delivery systems for antitumor multi-drug combinational application
    JIANG Wen-xin, ZHANG Hua-qing, DING Yang, ZHOU Jian-ping
    2022, 57(1):1-12. DOI:10.16438/j.0513-4870.2021-0787
    Abstract PDF
    Tumor immune checkpoint therapy and the drug delivery strategies
    LI Pei-shan#, LIU Yi-xuan#, XIE Ying#, REN Yu-xin, CHEN Ming, WANG Gui-ling, L&#, Wan-liang, , , , ,
    2022, 57(1):13-24. DOI:10.16438/j.0513-4870.2021-1150
    Abstract PDF
    Advances in polydopamine-based drug delivery systems for tumor targeting
    SU Yu-pei, PAN Hao, LIU Dan-dan, WANG Jia-hui, DING Ping-tian, PAN Wei-san
    2022, 57(1):25-35. DOI:10.16438/j.0513-4870.2021-1151
    Abstract PDF
    Advance on inducing ferroptosis of tumor cells based on nanodelivery technology
    ZHANG Shen-wu, SHAN Xin-zhu, SUN Xin-xin, KONG Zhi-qiang, LUO Cong, HE Zhong-gui
    2022, 57(1):36-45. DOI:10.16438/j.0513-4870.2021-1152
    Abstract PDF
    Progress on active tumor-targeting nano drug delivery systems for improving tumor immunotherapy
    YAN Wen-lu, LANG Tian-qun, YIN Qi, LI Ya-ping
    2022, 57(1):46-63. DOI:10.16438/j.0513-4870.2021-1172
    Abstract PDF
    Research progress of histidine-based tumor-targeting drug delivery systems
    JI Meng, CHEN Da-li, TU Jia-sheng, SUN Chun-meng
    2022, 57(1):64-75. DOI:10.16438/j.0513-4870.2021-1174
    Abstract PDF
    Research progress of endoplasmic reticulum targeting drug delivery system for anti-tumor immunotherapy
    CHEN Li-qiang, SHEN Xin-ran, HUANG Yuan
    2022, 57(1):76-84. DOI:10.16438/j.0513-4870.2021-1213
    Abstract PDF
    Recent advances of cell membrane-derived biomimetic nanotechnology in cancer targeted drug delivery system
    HUANG Ling-ling, WU Hong-hui, XU Dong-hang, GAO Jian-qing
    2022, 57(1):85-97. DOI:10.16438/j.0513-4870.2021-1231
    Abstract PDF
    Strategies for targeting and remodeling tumor microenvironment
    YANG Meng-meng, HAN Xiao-peng, QIN Chao, YANG Lei, YIN Li-fang
    2022, 57(1):98-108. DOI:10.16438/j.0513-4870.2021-1232
    Abstract PDF
    Research progress of tumor microenvironment-responsive RNA drug delivery systems
    LU An, WANG Xiang-yu, YAN Yi, WANG Jian-cheng
    2022, 57(1):109-121. DOI:10.16438/j.0513-4870.2021-1251
    Abstract PDF
    Research advances on antitumor mechanism of NK cells and its application in cancer targeted therapy
    ZHANG Shu-fen, ZENG Ying-ping, MENG Ting-ting, YUAN Hong, HU Fu-qiang
    2022, 57(1):122-133. DOI:10.16438/j.0513-4870.2021-1253
    Abstract PDF
    Progress and prospect in the clinical translation of cancer nanomedicine
    WANG Zhao-hui, LIU Yu-ling
    2022, 57(1):134-141. DOI:10.16438/j.0513-4870.2021-1259
    Abstract PDF
    Advances of microneedle vaccines in transcutaneous immunization
    CHEN Yang-yan, HUANG Yao, HU Wan-shan, DU Min-qun, PENG Ting-ting, PAN Xin, WU Chuan-bin
    2022, 57(1):142-149. DOI:10.16438/j.0513-4870.2021-1297
    Abstract PDF
    Research progress of exosomes based targeted delivery of antitumor drugs
    XING Hao-nan, LU Mei, LIU Ying-qi, DONG Yu-han, ZHENG Ai-ping
    2022, 57(1):150-158. DOI:10.16438/j.0513-4870.2021-1354
    Abstract PDF
    Recent advances in neonatal Fc receptor targeted drug delivery systems
    HE Miao, PENG Bao-wei, XU Yu-hong
    2022, 57(1):159-168. DOI:10.16438/j.0513-4870.2021-1636
    Abstract PDF
    The effect of pH transition points of ultra-pH sensitive fluorescent nanoprobes on tumor imaging efficiency
    DI Shi-ming, GONG Li-dong, ZHUANG Feng, LIU Wei, LIN Zhi-qiang, ZHANG Qiang
    2022, 57(1):169-177. DOI:10.16438/j.0513-4870.2021-0906
    Abstract PDF
    Tumor microenvironment responsive liposomes blocking CXCL12/CXCR4 pathway and synergistically enhancing immune efficacy of anti-PD-L1
    WANG Ru-dong, PENG Yi-wei, YANG Zhen-zhen, DU Yi-tian, LIN Meng, SUN Qi, QI Xian-rong
    2022, 57(1):178-187. DOI:10.16438/j.0513-4870.2021-0967
    Abstract PDF
    Preparation and targeting evaluation of reductant-sensitive oxaliplatin-loaded Fe3O4 nanoparticles
    WANG Yu#, CHEN Qin-jun#, SUN Tao, JIANG Chen
    2022, 57(1):188-199. DOI:10.16438/j.0513-4870.2021-1000
    Abstract PDF
    Co-delivery of Tim-3 mAb and sorafenib enhanced chemoimmunotherapy for hepatocellular carcinoma using “responsive shell-peeling” mesoporous silica nanoparticles
    MU Sheng-jun#, SANG Xiao#, MU Wei-wei, WANG Tian-qi, YANG Rui, ZHANG Zi-peng, LIU Yong-jun, ZHANG Na
    2022, 57(1):200-210. DOI:10.16438/j.0513-4870.2021-1190
    Abstract PDF
    Construction and anti-tumor efficiency evaluation of redox-responsive micelles for the co-delivery of IR-780 and 18β-glycyrrhetinic acid
    BAI Wen-jing, XIA Chun-yu, LI Man, LU Zheng-ze, HE Qin
    2022, 57(1):211-221. DOI:10.16438/j.0513-4870.2021-1235
    Abstract PDF
    Anti-tumor activity of yeast vesicle biomimetic nanomedicine with the ability of active tumor penetration
    LIU Jun-jie#, XU Li-hua#, ZHANG Kai-xiang, ZHAO Xiu, WANG Yi-yang, SHI Jin-jin, ZHANG Zhen-zhong
    2022, 57(1):222-232. DOI:10.16438/j.0513-4870.2021-1240
    Abstract PDF
    Folic acid-modified phospholipid-encapsulated paclitaxel nanocrystals for preoperative chemotherapy of gastric cancer
    WANG Jun, HUANG Guang-jian, LIU Yu, LU Wei-yue
    2022, 57(1):233-241. DOI:10.16438/j.0513-4870.2021-1247
    Abstract PDF
    Highly penetrable nanoparticles co-loading doxorubicin and IDO1 siRNA enhance tumor immunotherapy
    SHI Meng-hao, WANG Yu, HAN Yan-yan, ZHANG Jiu-long, WU Shi-yang, CHEN Da-wei
    2022, 57(1):242-250. DOI:10.16438/j.0513-4870.2021-1352
    Abstract PDF

    Recommend